NDA supported by positive efficacy and safety data from the Phase 2 and pivotal Phase 3 trials of roflumilast foam If approved, roflumilast foam would be the first topical drug for seborrheic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results